Hydroxyurea vs RBC transfusion: Proportion of participants developing new or progressive SCI lesions
It is very uncertain whether hydroxyurea changes proportion of participants developing new or progressive SCI lesions compared with RBC transfusion (very low certainty).
What each review found
Include earlier review versions| Finding | Effect | Studies | GRADE certainty |
|---|---|---|---|
Hydroxyurea vs RBC transfusion Proportion of participants developing new or progressive SCI lesions · prevention of SCI in people with SCD who had a stroke (secondary prevention) It is very uncertain whether hydroxyurea changes proportion of participants developing new or progressive SCI lesions compared with RBC transfusion (very low certainty). Interventions for preventing silent cerebral infarcts in people with sickle cell disease (2020) · Cochrane Headline outcomes only | Peto OR 7.28 [0.14, 366.91] | 1 study · 133 participants | Very low |
Findings are shown side by side, never pooled across reviews.
The reviews
| Review | Searched up to | Included studies | AMSTAR 2 |
|---|---|---|---|
| Interventions for preventing silent cerebral infarcts in people with sickle cell disease 2020 · Cochrane Headline outcomes only | Not reported | list not extracted yet | Not assessed |
Studies behind the findings
None of these reviews ties its included studies to this outcome in the data here. Cochrane reviews and reviews with headline outcomes only do not list their studies yet.
How reviews are matched to this question
Reviews word the same question differently. Four decision models (TypeSafe's Jev, Liquid AI's d1-ultra, SubQ Snap and Baseten's Elephant) judged each wording of the population, intervention, comparator and outcome against the others; two wordings count as the same when at least three of them agree and none clearly disagrees, and findings count as this question only when all four elements match. Timing, setting and subgroup never split a question: they are shown on each finding.